This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
Little DJ, et al. Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia. Clinical Nephrology 81: 259-68, No. 4, Apr 2014. Available from: URL: http://doi.org/11324 [pii]
Rights and permissions
About this article
Cite this article
Sodium polystyrene sulfonate still best option in hyperkalemia. PharmacoEcon Outcomes News 700, 9 (2014). https://doi.org/10.1007/s40274-014-1174-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1174-7